NASDAQ | DRNA

$2.63 0.00 (0.000%)

3 month stock price graph

4:00 PM ET on Mar 22, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Mar 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences: ...
Feb 25, 2016
Data from Asia TIDES Presentation Suggest Feasibility of Proprietary Approach for Delivery of RNAi-based Therapy to the Liver via Subcutaneous or Intravenous Injection CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of ...
Feb 4, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcar...
Dec 31, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensat...
Dec 21, 2015
- Company Expects to Initiate Phase 1 Trial in Patients with PH1 in Early 2016 - - Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 - - Company Identifies DsiRNA-EX-Conjugate Clinical Candidates Targeting HAO1 Gene for Subcutaneous (SC)...
Dec 21, 2015
Company Expects to Achieve Proof-of-Concept for DCR-MYC in 2H 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DC...
Dec 16, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December 21, 2015. ...
Dec 15, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also...
Nov 13, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences: ...
Nov 10, 2015
-Management to Host Conference Call Today at 4:30 pm ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based investigational therapeutics targeting rare inherited diseases involving the liver and for...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase